Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Hepatic Impairment Clear all

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

NCT01299454

View directory record Official record

Conditions: Schizophrenia
Interventions: OPC-34712; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Miami, Florida • Minneapolis, Minnesota • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Oct 19, 2015 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional

Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment

NCT02150733

View directory record Official record

Conditions: Hepatic Impairment, Solid Tumor, Cancer
Interventions: Tivantinib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older

Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Hackensack, New Jersey

Source: ClinicalTrials.gov public record

Updated Feb 11, 2019 · Synced May 21, 2026, 11:10 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320

View directory record Official record

Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424

View directory record Official record

Conditions: Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions: BAY1817080, Midazolam; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jan 19, 2023 · Synced May 21, 2026, 11:10 PM EDT

Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-53718678 in Participants With Hepatic Impairment

NCT04332523

View directory record Official record

Conditions: Hepatic Impairment
Interventions: JNJ-53718678; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jun 12, 2022 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479

View directory record Official record

Conditions: Migraine
Interventions: lasmiditan 200 mg; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Kentucky

Source: ClinicalTrials.gov public record

Updated Nov 26, 2019 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

NCT02397707

View directory record Official record

Conditions: HCV Infection
Interventions: Voxilaprevir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Apr 8, 2020 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

NCT03359850

View directory record Official record

Conditions: Ovarian Neoplasms, Neoplasms, Solid Tumor, Hepatic Impairment
Interventions: Niraparib; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • Newport Beach, California • Aurora, Colorado + 2 more

Source: ClinicalTrials.gov public record

Updated May 27, 2021 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

NCT04823702

View directory record Official record

Conditions: Impaired Hepatic Function
Interventions: Aldafermin; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jan 18, 2022 · Synced May 21, 2026, 11:10 PM EDT

Recruiting Phase 1 Interventional

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

NCT04617522

View directory record Official record

Conditions: Advanced or Metastatic Solid Tumor, Liver Failure
Interventions: Sacituzumab Govitecan-hziy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Long Beach, California • Newark, Delaware • Baltimore, Maryland + 3 more

Source: ClinicalTrials.gov public record

Updated Feb 10, 2026 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05404529

View directory record Official record

Conditions: Hepatic Impairment
Interventions: Tavapadon; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated May 29, 2023 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

NCT01732263

View directory record Official record

Conditions: Hepatic Impairment, Healthy
Interventions: SSP-004184; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jul 18, 2021 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

NCT02063230

View directory record Official record

Conditions: Solid Tumors
Interventions: Selumetinib 50mg, Selumetinib 25mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jul 20, 2016 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

NCT01817985

View directory record Official record

Conditions: Chronic Hepatitis C
Interventions: GS-5816; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Aug 28, 2013 · Synced May 21, 2026, 11:10 PM EDT

Terminated Phase 1 Interventional

Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085

View directory record Official record

Conditions: Impaired Hepatic Function, Healthy
Interventions: ALXN2050; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed

Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Mar 18, 2025 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

NCT00418626

View directory record Official record

Conditions: Healthy
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years · Male only

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Source: ClinicalTrials.gov public record

Updated Mar 7, 2012 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

NCT03722823

View directory record Official record

Conditions: Hepatic Impairment
Interventions: Tucatinib; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Tustin, California • Orlando, Florida • Knoxville, Tennessee + 1 more

Source: ClinicalTrials.gov public record

Updated May 19, 2019 · Synced May 21, 2026, 11:10 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

NCT05045482

View directory record Official record

Conditions: Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
Interventions: Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Source: ClinicalTrials.gov public record

Updated Feb 16, 2026 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

NCT00359177

View directory record Official record

Conditions: Vomiting
Interventions: GW679769; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Gainesville, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Sep 24, 2017 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

NCT06529796

View directory record Official record

Conditions: Focal Segmental Glomerulosclerosis (FSGS)
Interventions: IXP; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • St. Petersburg, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jan 19, 2025 · Synced May 21, 2026, 11:10 PM EDT

Withdrawn Phase 1 Interventional

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

NCT04398680

View directory record Official record

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Tucson, Arizona • Beverly Hills, California • Plantation, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Dec 3, 2025 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Results available

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

NCT01949545

View directory record Official record

Conditions: Solid Tumors, Hematologic Malignancies, Hepatic Impairment
Interventions: Carfilzomib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older

Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Detroit, Michigan • Durham, North Carolina • Canton, Ohio + 2 more

Source: ClinicalTrials.gov public record

Updated May 1, 2017 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

NCT06340347

View directory record Official record

Conditions: Liver Diseases
Interventions: Osivelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Lake Forest, California • Tampa, Florida • Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jan 9, 2025 · Synced May 21, 2026, 11:10 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

NCT04639115

View directory record Official record

Conditions: Liver Diseases, Digestive System Diseases
Interventions: Ozanimod; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jun 13, 2022 · Synced May 21, 2026, 11:10 PM EDT